Amgen (AMGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Amgen (AMGN) reported robust Q2 2025 results, with revenue of $9.18 billion and EPS of $6.02, significantly exceeding consensus estimates by 3.52% and 14.45% respectively. Despite this top-line beat, product performance was mixed, highlighted by substantial year-over-year declines in Neulasta (-21.9%) and Enbrel (-33.6%), though strong growth from BLINCYTO (+45.5%) and Vectibix (+13%) contributed to overall product sales growth of 9.1%. The stock has outperformed the S&P 500 over the past month, returning +3.1%.

Analysis

Amgen delivered a strong Q2 2025 performance on the headline figures, reporting revenue of $9.18 billion and EPS of $6.02, which surpassed consensus estimates by 3.52% and 14.45% respectively. This top-line growth of 9.4% year-over-year was driven by a 9.1% increase in total product sales and a notable 17.6% rise in 'Other revenues', which itself beat analyst projections. However, a deeper look into the product portfolio reveals a mixed and challenging landscape. Significant revenue erosion continues in key legacy products, with Enbrel sales plummeting 33.6% year-over-year to $604 million, substantially missing the $804.22 million estimate. Similarly, Neulasta sales declined 21.9% to $82 million, also falling short of expectations. These declines were offset by robust growth in newer assets, particularly BLINCYTO, which surged 45.5% year-over-year, and Vectibix, which grew 13%. While the overall results are positive and the stock has outperformed the S&P 500 by 2.1 percentage points over the past month, the underlying weakness in major, established franchises remains a critical factor for assessing the firm's long-term growth trajectory.

Key Decisions for Investors

• Investors should scrutinize the sustainability of Amgen's growth, as the strong headline beat masks significant revenue erosion in key legacy products like Enbrel and Neulasta.
• The outperformance of growth assets such as BLINCYTO is critical; therefore, monitoring the sales trajectory of this and other newer products against the decline of older ones is essential for gauging the success of the company's portfolio transition.
• Given the stock's recent 3.1% gain and the 'Hold' rating, investors might consider whether the positive earnings surprise is already priced in, warranting a cautious stance pending further clarity on future product performance.